Consumer Medicine Information (CMI) summary
The
full CMI on the next page has more details. If you are worried about using this medicine,
speak to your doctor or pharmacist.
This medicine is new or being used differently. Please report side effects. See the
full CMI for further details.
1. Why am I using BAVENCIO?
BAVENCIO contains the active ingredient, avelumab. BAVENCIO is used to treat certain
types of cancer.
2. What should I know before I use BAVENCIO?
Do not use if you have ever had an allergic reaction to BAVENCIO or any of the ingredients
listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines,
or are pregnant or plan to become pregnant or are breastfeeding.
3. What if I am taking other medicines?
Some medicines may interfere with BAVENCIO and affect how it works.
4. How do I use BAVENCIO?
Prior to the first four infusions of BAVENCIO, you will be given paracetamol and an
antihistamine. For subsequent infusions, these medicines will only be given if your
doctor believe this is necessary.
You will receive BAVENCIO as an infusion (a drip) into a vein (intravenously) over
a period of 60 minutes, once every 2 weeks.
5. What should I know while using BAVENCIO?
Things you should do
|
Remind any doctor, nurse, dentist or pharmacist you visit that you are using BAVENCIO.
|
Driving or using machines
|
Treatment-related symptoms can affect your concentration and ability to react.
|
6. Are there any side effects?
Common side effects include feeling tired or weak; muscle, back, stomach area or joint
pain; loose stools, vomiting, nausea, constipation; swelling in the arms, feet or
legs; feeling less hungry, weight loss; cough; rash, itching, redness of the skin;
fever, chills; shortness of breath; dizziness, headache; high blood pressure; low
blood pressure; flushing; difficulty in speaking or breathing, hoarseness; urinary
tract infection such as burning sensation when urinating, strong or frequent urge
to urinate.
Serious side effects include infusion-related reactions; problems due to inflammation
of your lungs (pneumonitis); problems with your liver (hepatitis or liver toxicity
when used in combination with axitinib); problems with your intestines (colitis) or
diarrhoea; problems with your hormone producing glands (including the thyroid, pituitary,
and adrenal glands); problems with your pancreas (pancreatitis); Type 1 diabetes,
including a serious, sometimes life-threatening problem due to increased acid in the
blood produced from diabetes (diabetic ketoacidosis); problems with your kidneys;
problems with your muscles (myositis, myasthenia gravis/myasthenic syndrome, polymyalgia
rheumatica); problems with your bile ducts (sclerosing cholangitis), problems with
your joints (arthritis), problems with your glands that make moisture for the body
(Sjögren’s syndrome), problems with your heart (myocarditis or major adverse cardiovascular
events when used in combination with axitinib); problems with your eyes (uveitis);
an immune system disorder that can cause nerve inflammation (Guillain-Barré Syndrome).
This medicine is subject to additional monitoring. This will allow quick identification
of new safety information. You can help by reporting any side effects you may get.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems .
Active ingredient:
avelumab (rch)
Full Consumer Medicine Information (CMI)
This leaflet provides important information about using BAVENCIO. You should also speak to your doctor or pharmacist if you would like further information
or if you have any concerns or questions about using BAVENCIO.
Where to find information in this leaflet:
1. Why am I using BAVENCIO?
BAVENCIO contains the active ingredient, avelumab. BAVENCIO is a monoclonal antibody, which is a protein designed to recognise and attach
to a specific target in the body to help the immune system attack and destroy cancer
cells.
BAVENCIO is used to treat a rare type of skin cancer called metastatic Merkel cell
carcinoma (mMCC) where the disease has spread; a type of cancer in the bladder or
urinary tract called urothelial carcinoma, when the disease is advanced or metastatic
but has not progressed with platinum-based chemotherapy; or a type of kidney cancer
called renal cell carcinoma (RCC), when it is advanced, in combination with another
medicine, axitinib. It is important that you also read the Consumer Medicine Information
for axitinib. If you have any questions about axitinib, ask your doctor.
2. What should I know before I use BAVENCIO?
Warnings
Do not use BAVENCIO if:
you are allergic to avelumab, or any of the ingredients listed at the end of this
leaflet.
Always check the ingredients to make sure you can use this medicine.
Check with your doctor if you:
have any other medical conditions, including an autoimmune disease (a condition where
the body attacks its own cells) like Crohn's, Guillain- Barré, ulcerative colitis
or lupus. If you already have an autoimmune disease, your risk of immune-mediated
side effects may be higher as BAVENCIO may cause inflammation in parts of your body.
You may also experience frequent flares of your autoimmune disease, which in the majority
of cases are mild; human immunodeficiency virus (HIV) infection or acquired immune
deficiency syndrome (AIDS); hepatitis B or hepatitis C; have had an organ transplant
take any medicines for any other condition, including medicines that suppress your
immune system
Once you are treated with BAVENCIO, your doctor may give you corticosteroids to reduce
any possible side effects that you may have during your treatment.
During treatment, you may be at risk of developing certain side effects. It is important
you understand these risks and how to monitor for them. See additional information
under Section
6. Are there any side effects?
Talk to your doctor or nurse before receiving BAVENCIO as it may cause:
problems due to inflammation of your lungs (pneumonitis)
problems with your liver (hepatitis or liver toxicity when used in combination with
axitinib)
problems with your intestines (colitis) or diarrhoea
problems with your hormone producing glands (including the thyroid, pituitary, and
adrenal glands)
problems with your pancreas (pancreatitis)
Type 1 diabetes, including a serious, sometimes life-threatening problem due to increased
acid in the blood produced from diabetes (diabetic ketoacidosis).
problems with your kidneys
problems with your muscles (myositis, myasthenia gravis/myasthenic syndrome, polymyalgia
rheumatica)
problems with your bile ducts (sclerosing cholangitis)
problems with your joints (arthritis)
problems with your glands that make moisture for the body such as tears and saliva
(Sjögren’s syndrome)
problems with your heart (myocarditis or major adverse cardiovascular events such
as trouble breathing, chest discomfort, or swelling of lower legs or hands when used
in combination with axitinib)
problems with your eyes (uveitis)
an immune system disorder that can cause nerve inflammation (Guillain-Barré Syndrome)
infusion-related reactions
In addition, autoimmune haemolytic anaemia (headaches, short of breath, looking pale,
and yellowing of the skin and/or eyes) and systemic inflammatory response syndrome
(redness and swelling in the affected parts of your body, pain, loss of function of
parts of your body, fatigue, fast heart rate, abnormal breathing, fever or low body
temperature, shaking or chills, warm or clammy/sweaty skin, rash, confusion, agitation
or other mental changes, loss of consciousness) have been reported with BAVENCIO or
other products in this class (PD-1/PD-L1 blocking antibodies).
Should any of the above occur, your doctor may give you other medicines in order to
prevent complications and reduce your symptoms; withhold the next dose of BAVENCIO;
or stop your treatment with BAVENCIO altogether.
Pregnancy and breastfeeding
Check with your doctor if you are pregnant or intend to become pregnant.
BAVENCIO must not be used during pregnancy as it may cause harm to your unborn baby.
Make sure you maintain adequate contraception during treatment and for at least one
month after your last dose.
Talk to your doctor if you are breastfeeding or intend to breastfeed.
It is unknown if BAVENCIO is passed into your breast milk. A risk to the breast-fed
infant cannot be excluded.
You should not breastfeed during treatment and for at least one month after your last
dose.
Use in children
For mMCC, the effectiveness of BAVENCIO in children under the age of 12 years has
not been established.
3. What if I am taking other medicines?
Tell your doctor or pharmacist if you are taking any other medicines, including any
medicines, vitamins or supplements that you buy without a prescription from your pharmacy,
supermarket or health food shop.
Some medicines may interfere with BAVENCIO and affect how it works.
These include medicines that make your immune system weak, such as steroids.
Check with your doctor or pharmacist if you are not sure about what medicines, vitamins
or supplements you are taking and if these affect BAVENCIO.
4. How do I use BAVENCIO?
Prior to the first four infusions of BAVENCIO, you will be given paracetamol and an
antihistamine. For subsequent infusions, these medicines will only be given if your
doctor believe this is necessary. These premedications are given to help minimise
potential reactions to the BAVENCIO infusion.
How much to use
A doctor experienced in the use of medicines for cancer will supervise your treatment
with BAVENCIO.
Depending on your cancer, the recommended dose is either 10 mg per kg of your body
weight or 800 mg of BAVENCIO.
BAVENCIO has to be diluted with 0.9% or 0.45% saline solution before use.
Your doctor will calculate the correct dose and dilution for you.
When to use BAVENCIO
You will receive BAVENCIO as an infusion (a drip) into a vein (intravenously) over
a period of 60 minutes, once every 2 weeks.
Your doctor will decide how long you will receive BAVENCIO based on your response
to the medicine and the type of cancer you have.
If you use too much BAVENCIO
As BAVENCIO is given to you under the supervision of your doctor, it is very unlikely
that you will receive too much.
However, if you think that you have used too much BAVENCIO, you may need urgent medical
attention.
You should immediately:
phone the Poisons Information Centre
(by calling
13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.
You should do this even if there are no signs of discomfort or poisoning.
5. What should I know while using BAVENCIO?
Things you should do
Keep all appointments with your doctor so that your progress can be checked. Your
doctor may do blood tests or other laboratory tests from time to time to prevent unwanted
side effects during your treatment with BAVENCIO.
If you miss an appointment, talk to your doctor or nurse and arrange another visit
as soon as possible.
Call your doctor straight away if you:
Become pregnant while you are being treated with BAVENCIO
Remind any doctor, nurse, dentist or pharmacist you visit that you are using BAVENCIO.
Driving or using machines
Be careful before you drive or use any machines or tools until you know how BAVENCIO
affects you.
Treatment-related symptoms can affect your concentration and ability to react.
6. Are there any side effects?
All medicines can have side effects. If you do experience any side effects, most of
them are minor and temporary. However, some side effects may need medical attention.
See the information below and, if you need to, ask your doctor or pharmacist if you
have any further questions about side effects.
Be aware of important symptoms of inflammation. BAVENCIO acts on your immune system
and may cause inflammation in parts of your body. Inflammation may cause serious damage
to your body and some inflammatory conditions may be life-threatening and need treatment
or withdrawal of BAVENCIO.
Less serious side effects
Serious side effects
Tell your doctor or pharmacist if you notice anything else that may be making you
feel unwell.
Other side effects not listed here may occur in some people.
Reporting side effects
After you have received medical advice for any side effects you experience, you can
report side effects to the Therapeutic Goods Administration online at
www.tga.gov.au/reporting-problems . By reporting side effects, you can help provide more information on the safety of
this medicine.
Always make sure you speak to your doctor or pharmacist before you decide to stop
taking any of your medicines.
7. Product details
This medicine is only available with a doctor's prescription.
What BAVENCIO contains
Active ingredient
(main ingredient)
|
avelumab (rch)
|
Other ingredients
(inactive ingredients)
|
Mannitol, glacial acetic acid, polysorbate 20, sodium hydroxide, water for injections
|
Potential allergens
|
N/A
|
Do not take this medicine if you are allergic to any of these ingredients.
What BAVENCIO looks like
BAVENCIO is a clear, colourless, to slightly yellow solution. It is supplied in 10
mL colourless glass vials with a rubber stopper and aluminium seal. Each pack contains
1 vial. (Aust R 282729).
Who distributes BAVENCIO
Merck Healthcare Pty Ltd
Suite 1, Level 1
Building B
11 Talavera Road
Macquarie Park NSW 2113
Medical Information: 1800 633 463
This leaflet was prepared in July 2024.
® Registered trademark of Merck KGaA, Darmstadt, Germany